Qingya W. Cui

Suzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

BiRD Regimen Followed by Anti-BCMA CAR-T Cell Immunotherapy as First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 2 Trial.

BiRD Regimen Followed by Anti-BCMA CAR-T Cell Immunotherapy as First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 2 Trial.

Journal: American journal of hematology

Published: December 27, 2025

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations.

Journal: Journal of translational medicine

Published: December 07, 2025

Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.

Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.

Journal: Infectious diseases and therapy

Published: June 12, 2025

Treatment outcome and efficacy of desensitization strategies for immunized-PTR in hematological malignancies before hematopoietic stem cell transplantation.

Treatment outcome and efficacy of desensitization strategies for immunized-PTR in hematological malignancies before hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation

Published: March 19, 2025

Tandem CD19/CD22 CAR T-Cell Therapy as First-Line Treatment for Adult Patients With High-Risk Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia.

Tandem CD19/CD22 CAR T-Cell Therapy as First-Line Treatment for Adult Patients With High-Risk Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia.

Journal: American journal of hematology

Published: February 17, 2025

Construction and Validation of an Assistant Decision-Making Model for Platelet Transfusion Refractoriness in Patients with Acute Myeloid Leukemia.

Construction and Validation of an Assistant Decision-Making Model for Platelet Transfusion Refractoriness in Patients with Acute Myeloid Leukemia.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: October 07, 2024

Familial Acute Promyelocytic Leukemia: A Case Report and Review of the Literature.

Familial Acute Promyelocytic Leukemia: A Case Report and Review of the Literature.

Journal: OncoTargets and therapy

Published: June 14, 2024

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Journal: Leukemia research

Published: May 25, 2024

Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.

Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: March 29, 2024

Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.

Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.

Journal: Annals of hematology

Published: December 18, 2023

Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.

Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Annals of hematology

Published: December 12, 2023

Single-Cell Spatial Transcriptomics Unveils Platelet-Fueled Cycling Macrophages for Kidney Fibrosis.

Single-Cell Spatial Transcriptomics Unveils Platelet-Fueled Cycling Macrophages for Kidney Fibrosis.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: November 08, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026